Singular Genomics Systems Stock Price To Sales
| OMIC Stock | USD 0.39 0.01 1.58% |
Singular Genomics Systems fundamentals help investors to digest information that contributes to Singular Genomics' financial success or failures. It also enables traders to predict the movement of Singular Stock. The fundamental analysis module provides a way to measure Singular Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Singular Genomics stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 11.51 | 10.93 |
Singular | Price To Sales |
Singular Genomics Systems Company Price To Sales Analysis
Singular Genomics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Singular Genomics Price To Sales | 10.86 X |
Most of Singular Genomics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Singular Genomics Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Singular Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Singular Genomics is extremely important. It helps to project a fair market value of Singular Stock properly, considering its historical fundamentals such as Price To Sales. Since Singular Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Singular Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Singular Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Singular Genomics Systems has a Price To Sales of 10.8645 times. This is 49.23% lower than that of the Health Care Equipment & Supplies sector and 56.94% lower than that of the Health Care industry. The price to sales for all United States stocks is 4.86% higher than that of the company.
Singular Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Singular Genomics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Singular Genomics could also be used in its relative valuation, which is a method of valuing Singular Genomics by comparing valuation metrics of similar companies.Singular Genomics is currently under evaluation in price to sales category among related companies.
Singular Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (23.39) % | ||||
| Current Valuation | (68.35 M) | ||||
| Shares Outstanding | 74.07 M | ||||
| Shares Owned By Insiders | 14.01 % | ||||
| Shares Owned By Institutions | 47.17 % | ||||
| Number Of Shares Shorted | 667.17 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.18 X | ||||
| Price To Sales | 10.86 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (24 K) | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (94.82 M) | ||||
| Cash And Equivalents | 287.98 M | ||||
| Cash Per Share | 4.05 X | ||||
| Total Debt | 75.29 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 22.98 X | ||||
| Book Value Per Share | 2.42 X | ||||
| Cash Flow From Operations | (73.65 M) | ||||
| Short Ratio | 5.95 X | ||||
| Earnings Per Share | (1.30) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 0.75 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.43 | ||||
| Market Capitalization | 28.23 M | ||||
| Total Asset | 265.47 M | ||||
| Retained Earnings | (337.6 M) | ||||
| Working Capital | 173.94 M | ||||
| Net Asset | 265.47 M |
About Singular Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Singular Genomics Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Singular Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Singular Genomics Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out Singular Genomics Piotroski F Score and Singular Genomics Altman Z Score analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Singular Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share 0.04 | Quarterly Revenue Growth 0.413 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.